Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Eli Lilly & Co.
Ionis Pharmaceuticals, Inc. Common Stock
Amgen Inc
Vertex Pharmaceuticals Inc
Prothena Corporation plc Ordinary Shares
Moderna, Inc. Common Stock
Gilead Sciences Inc
Bristol-Myers Squibb Co.
ABBVIE INC.
Johnson & Johnson
The chart shows the growth of an initial investment of $10,000 in Biogen Inc. Common Stock, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Biogen Inc. Common Stock (BIIB) has returned 1.12% so far this year and 45.59% over the past 12 months. Looking at the last ten years, BIIB has achieved an annualized return of -3.77%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Biogen Inc. Common Stock (BIIB) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.58% | 6.98% | -3.62% | -3.18% | ||||||||
| 2025 | -6.44% | -1.61% | -2.54% | -11.49% | 7.83% | -3.09% | 2.45% | 2.53% | 4.89% | 9.55% | 18.55% | -2.31% |
| 2024 | -4.23% | -11.58% | -0.84% | -0.40% | 4.35% | 2.89% | -7.87% | -5.12% | -5.08% | -10.59% | -7.50% | -4.52% |
| 2023 | 5.12% | -6.81% | 3.75% | 10.09% | -3.05% | -5.37% | -4.48% | -0.74% | -4.46% | -7.16% | -1.88% | 10.61% |
| 2022 | -5.89% | -7.11% | 0.01% | -2.38% | -3.05% | 0.96% | 4.72% | -8.66% | 37.08% | 5.37% | 7.67% | -9.36% |
| 2021 | 15.00% | -3.64% | 1.94% | -4.53% | -0.15% | 27.14% | -5.57% | 3.63% | -16.96% | -5.21% | -11.43% | 1.24% |
| 2020 | -10.10% | 13.96% | 2.51% | -3.88% | 4.07% | -12.49% | 2.92% | 4.71% | -1.32% | -11.54% | -5.31% | 1.50% |
| 2019 | 12.44% | -1.72% | -28.65% | -4.11% | -4.23% | 6.15% | 0.52% | -7.96% | 6.72% | 28.33% | 0.01% | 1.50% |
| 2018 | 8.30% | -17.00% | -4.96% | 0.58% | 6.94% | -1.59% | 15.18% | 5.26% | -0.15% | -14.36% | 9.62% | -10.17% |
| 2017 | -3.00% | 3.45% | -5.74% | -1.05% | -8.69% | 8.53% | 6.22% | 8.86% | -1.27% | -1.12% | 3.01% | -0.66% |
| 2016 | 6.24% | 5.46% | -16.03% | 19.52% | 1.88% | 1.65% | -10.49% | 5.01% | -4.30% |
The charts below present risk-adjusted performance metrics for Biogen Inc. Common Stock (BIIB) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of BIIB compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Biogen Inc. Common Stock volatility is 1.84%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 29.44B | 26.84B | 24.55B | 23.88B | 24.62B | 27.23B | 25.29B | 23.65B | 22.88B | 19.50B | 14.32B | 11.86B | 10.13B | 9.05B | 8.09B | 8.55B |
| Equity Attributable To Parent (USD) | 18.26B | 14.80B | 13.40B | 10.90B | 10.70B | 13.34B | 13.04B | 12.61B | 12.14B | 9.37B | 10.81B | 8.62B | 6.96B | 6.43B | 5.40B | 6.22B |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | -9.50M | 63.50M | -14.20M | -4.10M | -8.00M | -14.70M | -11.50M | 2.10M | 5.03M | 596.00K | 2.27M | 1.49M | 52.94M | 40.35M |
| Equity (USD) | 18.26B | 14.80B | 13.39B | 10.96B | 10.69B | 13.34B | 13.03B | 12.60B | 12.13B | 9.37B | 10.81B | 8.62B | 6.96B | 6.43B | 5.45B | 6.26B |
| Other Non-current Liabilities (USD) | 1.55B | 1.67B | 1.61B | 2.35B | 2.76B | 4.57B | 3.03B | 1.75B | 815.60M | 1.03B | 700.75M | 891.79M | 488.03M | 686.03M | 557.73M | - |
| Long-term Debt (USD) | 6.29B | 6.94B | 6.28B | 6.27B | 7.43B | 4.46B | 5.94B | 5.94B | 6.51B | 6.52B | 582.06M | 592.43M | 1.02B | 1.02B | 1.04B | - |
| Noncurrent Liabilities (USD) | 7.83B | 8.61B | 7.89B | 8.62B | 10.19B | 9.03B | 8.96B | 7.69B | 7.33B | 7.55B | 1.28B | 1.48B | 1.51B | 1.71B | 1.59B | 1.58B |
| Other Current Liabilities (USD) | 2.92B | 3.03B | 2.78B | 3.71B | 3.29B | 4.02B | 2.60B | 2.68B | 2.86B | 2.04B | 1.60B | 1.19B | 1.20B | 550.14M | 727.89M | 596.41M |
| Wages (USD) | - | - | - | - | - | 309.10M | 320.90M | 297.70M | 282.90M | 270.80M | 393.80M | 343.40M | 248.50M | 176.30M | 159.70M | - |
| Accounts Payable (USD) | 432.00M | 403.30M | 491.50M | 589.20M | 454.90M | 530.80M | 370.50M | 395.50M | 279.80M | 267.40M | 229.18M | 219.91M | 204.00M | 186.45M | 162.53M | 118.53M |
| Current Liabilities (USD) | 3.35B | 3.43B | 3.27B | 4.30B | 3.74B | 4.86B | 3.30B | 3.37B | 3.42B | 2.58B | 2.22B | 1.76B | 1.66B | 912.89M | 1.05B | 714.94M |
| Liabilities (USD) | 11.18B | 12.05B | 11.17B | 12.92B | 13.93B | 13.90B | 12.26B | 11.05B | 10.75B | 10.13B | 3.50B | 3.24B | 3.17B | 2.62B | 2.64B | 2.29B |
| Other Non-current Assets (USD) | 8.23B | 8.31B | 9.61B | 10.38B | 11.24B | 12.08B | 10.93B | 8.72B | 7.83B | 6.53B | 3.85B | 2.45B | 3.51B | 2.89B | 2.14B | 2.56B |
| Intangible Assets (USD) | 9.18B | 8.36B | 1.85B | 2.22B | 3.08B | 3.53B | 3.12B | 3.88B | 3.81B | 4.09B | 4.03B | 4.47B | 1.63B | 1.61B | 1.77B | 1.87B |
| Fixed Assets (USD) | 3.06B | 3.31B | 3.30B | 3.42B | 3.41B | 3.25B | 3.60B | 3.18B | 2.50B | 2.19B | 1.77B | 1.75B | 1.74B | 1.57B | 1.64B | 1.64B |
| Noncurrent Assets (USD) | 20.47B | 19.99B | 14.76B | 16.02B | 17.73B | 18.85B | 17.65B | 15.78B | 14.14B | 12.80B | 9.64B | 8.68B | 6.89B | 6.07B | 5.55B | 6.07B |
| Other Current Assets (USD) | 6.81B | 4.33B | 8.45B | 6.51B | 5.82B | 7.58B | 6.71B | 6.97B | 7.73B | 5.81B | 3.87B | 2.53B | 2.80B | 2.65B | - | 2.19B |
| Inventory (USD) | 2.17B | 2.53B | 1.34B | 1.35B | 1.07B | 804.20M | 929.90M | 902.70M | 1.00B | 893.40M | 804.02M | 659.00M | 447.37M | 326.84M | - | 293.95M |
| Current Assets (USD) | 8.97B | 6.86B | 9.79B | 7.86B | 6.89B | 8.38B | 7.64B | 7.87B | 8.73B | 6.70B | 4.67B | 3.18B | 3.24B | 2.98B | 2.54B | 2.48B |
| Assets (USD) | 29.44B | 26.84B | 24.55B | 23.88B | 24.62B | 27.23B | 25.29B | 23.65B | 22.88B | 19.50B | 14.32B | 11.86B | 10.13B | 9.05B | 8.09B | 8.55B |
Major M&A activity dominates the market with McCormick merging with Unilever's Foods business in a $29.1 billion deal, Sysco acquiring Jetro Restaurant Depot for $29 billion, and Eli Lilly acquiring Centessa Pharmaceuticals for $7.8 billion. Meanwhile, QVC faces financial distress and is considering Chapter 11 bankruptcy, while several other companies including IO Biotech and Lipella Pharmaceuticals have filed for bankruptcy.
Over 120 pharmaceutical companies are actively developing 140+ pipeline drugs for systemic lupus erythematosus (SLE), with approximately 30+ drugs in mid-stage development and 85+ in early stages. Key players include Roche, Biogen, Novartis, AbbVie, and Johnson & Johnson, with promising therapies targeting various mechanisms such as B cell inhibitors, JAK inhibitors, and TLR antagonists. Recent regulatory milestones include FDA Fast Track designation for nipocalimab and Breakthrough Therapy Designation for litifilimab.
U.S. equities staged their strongest rally in weeks on Tuesday following Trump's signals of willingness to end military hostilities with Iran. The S&P 500 advanced 1.8% to 6,456, though it remains down 6.2% for the month. Tech stocks led the recovery with the Nasdaq 100 rising 2%. Despite the rally, the S&P 500 is on track for its worst monthly performance since September 2022.
Biogen has agreed to acquire Apellis Pharmaceuticals for $41 per share in cash, valuing the deal at approximately $5.6 billion. The acquisition includes two FDA-approved therapies (Empaveli and Syfovre) with combined 2025 net sales of $689 million and expected mid-to-high teens growth through 2028. Apellis shares surged 136% to $40.36, while Biogen shares declined 4.60% to $178.94.
Biogen's stock rose 1.51% to $186.62 following FDA approval of a high-dose regimen for Spinraza, a treatment for spinal muscular atrophy (SMA). The approval is based on Phase 2/3 DEVOTE study data showing significant motor function improvements in treatment-naïve infants. Additionally, Biogen announced positive Phase 2 results for litifilimab in cutaneous lupus erythematosus, demonstrating statistically significant improvement versus placebo.
Biogen announced positive Phase 2 results from the AMETHYST study of litifilimab in cutaneous lupus erythematosus (CLE), meeting its primary endpoint with an 11.8% higher reduction in disease activity compared to placebo at Week 16. The drug demonstrated rapid improvement and was generally well tolerated, consistent with earlier positive LILAC trial results. Litifilimab received FDA Breakthrough Therapy Designation and could be the first targeted therapy for CLE in 70 years if approved.
The United States District Court for the District of Massachusetts has certified a class action lawsuit on behalf of purchasers of Biogen, Inc. securities during June 8 - July 12, 2021. The action alleges that Biogen and certain officers made material misrepresentations or omitted material facts in violation of federal securities laws. Defendants deny all allegations.
The global ALS therapeutics market is valued at USD 812 million in 2024 and is projected to reach USD 1,964 million by 2035, growing at an 11.5% CAGR. Growth is driven by innovations in genetic therapies, gene-silencing technologies, improved diagnostics, and increased disease awareness. Key players include Biogen, Ionis Pharmaceuticals, Amylyx Pharmaceuticals, and others developing disease-modifying treatments.
The global Alzheimer's Therapeutics Market is projected to surpass $6.0 billion in 2026, driven by rising disease prevalence and demand for disease-modifying therapies. Real-world evidence from lecanemab treatment shows strong patient continuation rates, supporting longer treatment durations. Market growth is fueled by increasing R&D investments and M&A activity, though challenges include skilled professional shortages and geopolitical risks from trade tariffs.
Biogen announced that Dr. Maria C. Freire has been elected as the new Chair of the Board of Directors, effective after the company's 2026 Annual Meeting on June 9, 2026. She will succeed Caroline Dorsa, who is retiring after 16 years on the board. Dr. Freire, who joined Biogen's board in 2021, brings extensive experience in biomedical innovation, drug development, and science policy. The leadership transition occurs as Biogen enters a catalyst-rich period with multiple clinical readouts expected in the next 18 months.